The potential NASH drug targets include peroxisome proliferator-activated receptor (PPAR), TGF-β1/Smad2, nuclear factor-κB (NF-κB), farnesoid X receptor (FXR), THR-β and MAPK Signal pathways (Kannt et al. 2021; Li et al. 2021; Liu et al. 2021). Here, NFKB1 is linked to metabolic dysfunction-associated steatohepatitis.